<DOC>
	<DOCNO>NCT01779947</DOCNO>
	<brief_summary>The purpose study compare safety efficacy generic Estradiol Vaginal Inserts , USP 10 mcg reference product Vagifem® 10 mcg determine whether efficacy 2 active treatment superior placebo .</brief_summary>
	<brief_title>Study Evaluate Safety Bioequivalence Estradiol Vaginal Inserts , 10 mcg Vagifem® 10 mcg Compare Placebo</brief_title>
	<detailed_description />
	<mesh_term>Vaginitis</mesh_term>
	<mesh_term>Atrophic Vaginitis</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Willing able provide understand write informed consent study . Healthy female subject age 30 75 year , inclusive , postmenopausal , define 12 month spontaneous amenorrhea 6 month spontaneous amenorrhea serum folliclestimulating hormone ( FSH ) level &gt; 40 mIU/mL , 6 week postsurgical bilateral oophorectomy without hysterectomy . At least 1 subjectassessed moderate severe symptom VVA among follow 4 symptom identify subject bothersome : Vaginal dryness Vaginal and/or vulvar irritation/itching Dysuria Vaginal pain associate sexual activity OR The presence vaginal bleeding associate sexual activity Had ≤ 5 % superficial cell vaginal smear cytology Visit 1 . Vaginal pH &gt; 5.0 Visit 1 . Systolic blood pressure ≤ 150 mm Hg diastolic blood pressure ≤ 90 mm Hg Visit 1 . If &gt; 40 year old , documentation negative mammogram ( obtain Visit 1 within 9 month prior Visit 1 ) . A radiology report document negative mammogram must available must take within 9 month Visit 1 obtain Visit 1 . Normal clinical breast examination Visit 1 . For woman intact uterus , vaginal ultrasonography confirmation Visit 1 inactive endometrial lining , endometrial thickness &lt; 4 mm . Documented Pap smear conduct within previous 12 month Visit 1 finding investigator believe would contraindicate use topical vaginal estradiol . In general good health clinically significant disease symptom VVA might interfere study evaluation . Was willing able understand comply requirement study , include apply medication instruct , return require study visit , comply therapy prohibition , able complete study . Known hypersensitivity estradiol vaginal tablet component study medication . A subject receive treatment list recently indicate washout period prior Visit 1/Screening/Baseline . Prohibited Medications ( Washout Period Prior Visit 1/Screening/Baseline ) Vaginal lubricant moisturizers ( least 48 hour ( 2 day ) ) Vaginal hormonal product ( ring , cream , gel ) ( least 1 week ( 7 day ) ) Transdermal estrogen alone estrogen/progestin product ( least 4 week ( 28 day ) ) Oral estrogen and/or progestin therapy ( least 8 week ( 56 day ) ) Intrauterine progestin therapy ( least 8 week ( 56 day ) ) Progestin implant estrogen alone injectable drug therapy ( least 3 month ( 90 day ) ) Estrogen pellet therapy progestin injectable drug therapy ( least 6 month ( 180 day ) ) Subject engage sexual intercourse within 48 hour ( 2 day ) Visit 1 . Screening mammogram clinical breast examination result indicate suspicion breast malignancy . History undiagnosed vaginal bleeding . Known bleed disorder . History significant risk factor endometrial cancer ( i.e. , tamoxifen use , prior pelvic radiation therapy , endometrial hyperplasia ) . For woman intact uterus , screen vaginal ultrasonography show endometrial thickness ≥ 4 mm . Known , suspect , history breast cancer cervical cancer . Known suspected estrogendependent neoplasia . History uncontrolled hypertension . Active deep vein thrombosis , pulmonary embolism , history condition . Active arterial thromboembolic disease ( e.g. , stroke myocardial infarction ) history condition . Known liver dysfunction disease . Known anaphylactic reaction angioedema estradiol vaginal tablet . Known protein C , protein S , antithrombin deficient , know thrombophilic disorder . Active vaginal herpes simplex infection know concurrent vaginal infection . Abnormal Pap smear within previous 12 month Visit 1 obtain Visit 1 . Any evidence malignancy premalignant change atypical squamous cell undetermined significance ( ASCUS ) Pap smear positive high risk human papillomavirus ( HPV ) . Any clinically significant condition situation ( include laboratory value ) condition study , opinion investigator , would interfere study evaluation optimal participation study . Use investigational drug device within 30 day sign ICF . Current participation clinical study involve investigational drug device . Consumed excessive amount alcohol , abuse drug , condition would compromise compliance protocol . Previous participation study . Subjects , opinion Investigator , would noncompliant requirement study protocol .</criteria>
	<gender>Female</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>